Analyst from Morgan Stanley's questions to Zai Lab Ltd (ZLAB) leadership • Q1 2024
Question
An analyst from Morgan Stanley inquired about the profile of the initial VYVGART patients, specifically the mix of treatment-naive versus refractory cases, and asked for a qualitative comparison of the market opportunity for future VYVGART indications versus the current GMG launch.
Answer
President and COO Josh Smiley explained that the initial launch targets patients who have not responded well to current treatments, so the majority are not treatment-naive. Dr. Harald Reinhart, President and Head of Global Development, added that the company is selective but committed to expanding into new indications like thyroid eye disease (TED) and myositis, which present significant opportunities.